PMB, a subsidiary of the ALCEN group, is proud to announce the launch of FLASHKNiFE, the FLASH radiotherapy system dedicated to clinical trials.
There is a long-standing history of FLASH at PMB which started in 2011. A prototype LINAC engineered to accelerate electrons in FLASH mode, the Oriatron 6e, was delivered in 2013 at Lausanne University Hospital (CHUV) and it started to deliver pre-clinical results soon after on several animal species (zebra fish, mice, cats, pigs…). FLASH proved to be a reproducible effect with a striking sparing of normal healthy tissues, while the effects on tumors were maintained the same amongst all the tumor models tested.
In 2019, the treatment of a first patient with FLASH therapy was performed successfully at CHUV using our Oriatron 6e technology for a patient with a skin refractory lymphoma. This first attempt showed that FLASH therapy was feasible and safe, notably due to an effective dose monitoring system (Bourhis et al Radiother Oncol 2019).
This successful and joint experience on FLASH with the CHUV made it possible for the development of FLASHKNiFE, a device specifically designed for FLASH radiotherapy. It will be able to administer a high single dose of radiation, for clinical applications such as skin cancer treatment and intra-operative radiotherapy (IORT). This system consists in an ultra-high dose rate LINAC mounted on a mobile base. It combines usability, flexibility and FLASH delivery mode, with precise configuration and monitoring. A first clinical prototype will soon be installed at the CHUV by PMB.
Our CEO, M. Marc Delmas, adds:
"We have been working with the pioneers of this fascinating subject, Lausanne University Hospital, for several years now. We believe that FLASHKNiFE is a breakthrough device in the field and the right tool to develop clinical applications and go on writing the history of FLASH radiotherapy."
PMB-Alcen Launches FLASHKNiFE RT System for Clinical Trials. Appl Rad Oncol.